share_log

Significant Results for Nyrada's Brain Injury Treatment

Significant Results for Nyrada's Brain Injury Treatment

Nyrada 腦損傷治療取得顯著成果
sharecafe ·  03/01 06:50

Nyrada Limited (ASX:NYR) CEO James Bonnar discusses results for using NYR-B103 to treat brain injuries.

Nyrada Limited(澳大利亞證券交易所股票代碼:NYR)首席執行官詹姆斯·邦納爾討論了使用 NYR-B103 治療腦損傷的結果。

Paul Sanger: I'm Paul Sanger for the Finance News Network, and today I'm talking to Nyrada Inc (ASX:NYR), and they have a market cap of $14m. Nyrada is a drug discovery and development company specialising in novel small-molecule therapeutics to treat neurological and cardiovascular diseases. Their brain injury program is seeking to develop therapies to reduce the long-term disability associated with stroke or traumatic brain injury by limiting the progressive cell death that occurs as a secondary brain injury. Today, we're talking to the company's Chief Executive Officer, James Bonnar. James, welcome back to the network.

保羅·桑格:我是金融新聞網的保羅·桑格,今天我在和Nyrada Inc(澳大利亞證券交易所股票代碼:NYR)談話,他們的市值爲1400萬美元。Nyrada是一家藥物發現和開發公司,專門研究治療神經系統和心血管疾病的新型小分子療法。他們的腦損傷計劃正在尋求開發療法,通過限制繼發性腦損傷發生的進行性細胞死亡,減少與中風或創傷性腦損傷相關的長期殘疾。今天,我們正在與該公司首席執行官詹姆斯·邦納爾交談。詹姆斯,歡迎回到網絡。

James Bonnar: Hi, Paul. Good to be here.

詹姆斯·邦納:嗨,保羅。很高興來到這裏。

Paul Sanger: Now, James, you've released some significant news to the market today, positive results for your preclinical study evaluating the efficacy of your brain injury program drug candidate NYR-B103. Can you please walk us through the study results?

保羅·桑格:現在,詹姆斯,你今天向市場發佈了一些重要消息,這是你評估腦損傷項目候選藥物 NYR-B103 療效的臨床前研究取得了積極成果。你能給我們介紹一下研究結果嗎?

James Bonnar: Certainly, Paul. So, the results we announced today were the result of a study in stroke. This was a study in a mouse model, and very pleasingly we were able to show in this study a better than 40 per cent neuroprotection, which certainly far exceeded our expectations. Also in this study, we were able to achieve a really strong signal in a blood injury biomarker. So, that supports the key finding. In addition to that, we also looked at safety in this study. So, we were pleased to report that there were no adverse effects in these animals that received our drug, so very, very pleasing results and happy to report them to the market.

詹姆斯·邦納:當然,保羅。因此,我們今天宣佈的結果是一項中風研究的結果。這是一項以小鼠模型進行的研究,非常令人高興的是,我們能夠在這項研究中顯示出超過40%的神經保護作用,這肯定遠遠超出了我們的預期。同樣在這項研究中,我們能夠在血液損傷生物標誌物中獲得非常強烈的信號。因此,這支持了關鍵發現。除此之外,我們還在這項研究中研究了安全性。因此,我們很高興地報告,這些接受我們藥物的動物沒有出現任何不良反應,因此結果非常非常令人滿意,並樂於向市場報告。

Paul Sanger: So just moving on, so what do these results actually mean for Nyrada and what would be the next steps for the brain injury program following these results?

保羅·桑格:那麼繼續前進,那麼這些結果對奈拉達到底意味着什麼?繼這些結果之後,腦損傷計劃的下一步將是什麼?

James Bonnar: So, this is a key inflection point for the program, and it sets up the way forward into some studies that we have to run. These are mandatory safety studies before we go into a first-in-human clinical study. So, this drug is novel, it's never been tested before. And before we go into a first-in-human study, which we're planning to run later in the year here in Australia, we have to test the drug in animals just to make sure that they tolerate it well and also identify the dose that we're going to take into the clinical study.

詹姆斯·邦納:所以,這是該計劃的關鍵轉折點,它爲我們必須進行的一些研究指明瞭前進的方向。在我們進行首次人體臨床研究之前,這些是強制性的安全性研究。因此,這種藥物是新穎的,以前從未進行過測試。在我們進行首次人體研究(我們計劃於今年晚些時候在澳大利亞進行這項研究)之前,我們必須在動物身上測試這種藥物,以確保它們能很好地耐受,並確定我們將在臨床研究中服用的劑量。

Paul Sanger: And look, a typical question I ask with biotechs, what discussions, if any, have you had with potential partners or is it too early to develop those conversations?

保羅·桑格:你看,我向生物技術公司問的一個典型問題是,你與潛在合作伙伴進行了哪些討論(如果有的話),還是現在展開這些對話還爲時過早?

James Bonnar: Well, it's fairly early in this program. I think there's a lot of interest in neurology drugs, particularly drugs that have first-in-class potential, which this drug does, and in therapeutic areas where there's unmet need, but also large commercial opportunities. So, we're developing this drug as a treatment for stroke, but also for traumatic brain injury. So, if you think of motor vehicle accidents, severe blows to the head, falls, etc. And the program that we're running really opens the door to two quite large and significant indications. These represent severe unmet clinical need. For example, here in Australia, stroke occurs about every 20 minutes. So, annually there are about 13 million strokes worldwide, and the numbers are similar for traumatic brain injury. So, we see this as a major step forward for the company and opening up quite a sizable commercial opportunity.

詹姆斯·邦納:嗯,現在這個項目還爲時過早。我認爲人們對神經病學藥物非常感興趣,尤其是具有同類首創潛力的藥物,這種藥物確實如此,以及需求未得到滿足但也有巨大商業機會的治療領域。因此,我們正在開發這種藥物既可以治療中風,也可以治療創傷性腦損傷。因此,如果你想到機動車事故、頭部受到嚴重打擊、跌倒等,而我們正在運行的項目確實爲兩個非常重要和重要的跡象打開了大門。這些代表了嚴重的未滿足的臨床需求。例如,在澳大利亞,中風大約每20分鐘發生一次。因此,全球每年約有1300萬中風,創傷性腦損傷的數字相似。因此,我們認爲這是公司向前邁出的重要一步,開闢了相當大的商業機會。

Paul Sanger: And just to close things up, James, what should investors be expecting over the next six months? Any data points they should be looking for? What can they expect?

保羅·桑格:總而言之,詹姆斯,投資者在未來六個月中應該期待什麼?他們應該尋找什麼數據點嗎?他們能期待什麼?

James Bonnar: So, we're just about to initiate those safety studies, so we'll be reporting readouts from those studies. We're also running a study with the Walter Reed Army Institute of Research, and this is a division of the US Department of Defense, and they were set up specifically to research traumatic brain injury, and they've been big supporters of the program and they have a model that we want to test the drug in, and it's a model of penetrating ballistic brain injury. So, it kind of reflects the sort of injuries that soldiers receive on the battlefield. So, that study's about to get underway and we'll be reporting on that and we'll be giving regular updates to the market as we progress forward to the clinic.

詹姆斯·邦納:因此,我們即將啓動這些安全性研究,因此我們將報告這些研究的結果。我們還在沃爾特·裏德陸軍研究所進行一項研究,這是美國國防部的一個部門,他們是專門爲研究創傷性腦損傷而成立的,他們一直是該計劃的大力支持者,他們有一個模型可以用來測試這種藥物,它是一個穿透彈道腦損傷的模型。因此,這在某種程度上反映了士兵在戰場上受到的傷害。因此,該研究即將開始,我們將對此進行報告,隨着我們進入臨床階段,我們將定期向市場提供最新情況。

Paul Sanger: James, a huge congratulations to yourself and to the broader team at Nyrada. Great to see these really impressive results, and we'll be watching the story very closely going forward.

保羅·桑格:詹姆斯,非常恭喜你自己和奈拉達更廣泛的團隊。很高興看到這些非常令人印象深刻的結果,未來我們將密切關注這個故事。

James Bonnar: Thanks, Paul.

詹姆斯·邦納:謝謝,保羅。

Ends

結束

1x1.png?futu_img_keep_extra_domain=1

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論